Literature DB >> 24569807

Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity.

Raffaello Cimbro1, Thomas R Gallant, Michael A Dolan, Christina Guzzo, Peng Zhang, Yin Lin, Huiyi Miao, Donald Van Ryk, James Arthos, Inna Gorshkova, Patrick H Brown, Darrell E Hurt, Paolo Lusso.   

Abstract

Elicitation of broadly neutralizing antibodies is essential for the development of a protective vaccine against HIV-1. However, the native HIV-1 envelope adopts a protected conformation that conceals highly conserved sites of vulnerability from antibody recognition. Although high-definition structures of the monomeric core of the envelope glycoprotein subunit gp120 and, more recently, of a stabilized soluble gp140 trimer have been solved, fundamental aspects related to the conformation and function of the native envelope remain unresolved. Here, we show that the conserved central region of the second variable loop (V2) of gp120 contains sulfated tyrosines (Tys173 and Tys177) that in the CD4-unbound prefusion state mediate intramolecular interaction between V2 and the conserved base of the third variable loop (V3), functionally mimicking sulfated tyrosines in CCR5 and anti-coreceptor-binding-site antibodies such as 412d. Recombinant gp120 expressed in continuous cell lines displays low constitutive levels of V2 tyrosine sulfation, which can be enhanced markedly by overexpression of the tyrosyl sulfotransferase TPST2. In contrast, virion-associated gp120 produced by primary CD4(+) T cells is inherently highly sulfated. Consistent with a functional role of the V2 sulfotyrosines, enhancement of tyrosine sulfation decreased binding and neutralization of HIV-1 BaL by monomeric soluble CD4, 412d, and anti-V3 antibodies and increased recognition by the trimer-preferring antibodies PG9, PG16, CH01, and PGT145. Conversely, inhibition of tyrosine sulfation increased sensitivity to soluble CD4, 412d, and anti-V3 antibodies and diminished recognition by trimer-preferring antibodies. These results identify the sulfotyrosine-mediated V2-V3 interaction as a critical constraint that stabilizes the native HIV-1 envelope trimer and modulates its sensitivity to neutralization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569807      PMCID: PMC3939864          DOI: 10.1073/pnas.1314718111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

2.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

3.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

4.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

5.  Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.

Authors:  Paolo Lusso; Patricia L Earl; Francesca Sironi; Fabio Santoro; Chiara Ripamonti; Gabriella Scarlatti; Renato Longhi; Edward A Berger; Samuele E Burastero
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

7.  Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility.

Authors:  Marie Pancera; Shahzad Majeed; Yih-En Andrew Ban; Lei Chen; Chih-chin Huang; Leopold Kong; Young Do Kwon; Jonathan Stuckey; Tongqing Zhou; James E Robinson; William R Schief; Joseph Sodroski; Richard Wyatt; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

8.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

9.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  18 in total

1.  HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.

Authors:  Paul W Keller; Orrianne Morrison; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

2.  Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1.

Authors:  Christina Guzzo; Jamie C Fox; Huiyi Miao; Brian F Volkman; Paolo Lusso
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

3.  Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing.

Authors:  Christina Guzzo; David Ichikawa; Chung Park; Damilola Phillips; Qingbo Liu; Peng Zhang; Alice Kwon; Huiyi Miao; Jacky Lu; Catherine Rehm; James Arthos; Claudia Cicala; Myron S Cohen; Anthony S Fauci; John H Kehrl; Paolo Lusso
Journal:  Sci Immunol       Date:  2017-05-12

4.  Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms.

Authors:  Kieran Cashin; Jasminka Sterjovski; Katherine L Harvey; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

5.  Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

Authors:  Marie Pancera; Tongqing Zhou; Aliaksandr Druz; Ivelin S Georgiev; Cinque Soto; Jason Gorman; Jinghe Huang; Priyamvada Acharya; Gwo-Yu Chuang; Gilad Ofek; Guillaume B E Stewart-Jones; Jonathan Stuckey; Robert T Bailer; M Gordon Joyce; Mark K Louder; Nancy Tumba; Yongping Yang; Baoshan Zhang; Myron S Cohen; Barton F Haynes; John R Mascola; Lynn Morris; James B Munro; Scott C Blanchard; Walther Mothes; Mark Connors; Peter D Kwong
Journal:  Nature       Date:  2014-10-08       Impact factor: 49.962

6.  Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.

Authors:  Kristina K Peachman; Nicos Karasavvas; Agnes-Laurence Chenine; Robert McLinden; Supachai Rerks-Ngarm; Kaewkungwal Jaranit; Sorachai Nitayaphan; Punnee Pitisuttithum; Sodsai Tovanabutra; Susan Zolla-Pazner; Nelson L Michael; Jerome H Kim; Carl R Alving; Mangala Rao
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

7.  Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.

Authors:  Andreas Loos; Johannes S Gach; Thomas Hackl; Daniel Maresch; Theresa Henkel; Andreas Porodko; Duc Bui-Minh; Wolfgang Sommeregger; Gordana Wozniak-Knopp; Donald N Forthal; Friedrich Altmann; Herta Steinkellner; Lukas Mach
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-28       Impact factor: 12.779

8.  Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.

Authors:  Derek D Sloan; Chia-Ying Kao Lam; Alivelu Irrinki; Liqin Liu; Angela Tsai; Craig S Pace; Jasmine Kaur; Jeffrey P Murry; Mini Balakrishnan; Paul A Moore; Syd Johnson; Jeffrey L Nordstrom; Tomas Cihlar; Scott Koenig
Journal:  PLoS Pathog       Date:  2015-11-05       Impact factor: 6.823

9.  Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Authors:  Kshitij Wagh; Tanmoy Bhattacharya; Carolyn Williamson; Alex Robles; Madeleine Bayne; Jetta Garrity; Michael Rist; Cecilia Rademeyer; Hyejin Yoon; Alan Lapedes; Hongmei Gao; Kelli Greene; Mark K Louder; Rui Kong; Salim Abdool Karim; Dennis R Burton; Dan H Barouch; Michel C Nussenzweig; John R Mascola; Lynn Morris; David C Montefiori; Bette Korber; Michael S Seaman
Journal:  PLoS Pathog       Date:  2016-03-30       Impact factor: 6.823

10.  Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex.

Authors:  Reda Rawi; Khalid Kunji; Abdelali Haoudi; Halima Bensmail
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.